文拉法辛与舍曲林治疗癫痫性抑郁障碍的对照研究

Comparative study of venlafaxine and sertraline in the treatment of epileptic depression

目的探讨文拉法辛和舍曲林治疗癫痫性抑郁障碍的疗效和安全性。方法将64例符合CCMD-3癫痫性抑郁障碍患者随机分为两组,在维持原抗癫痫药物的治疗基础上,分别给予文拉法辛和舍曲林治疗,疗程6周。采用汉密尔顿抑郁量表(HAMD)。汉密尔顿焦虑量表(HAMA)和副反应量表(TESS)评定疗效和不良反应。结果文拉法辛组显效率为83.3%,舍曲林组的显效率为76.7%。两者疗效相当。舍曲林组有2例引起癫痫发作次数增加,而文拉法辛对癫痫无明显影响。结论文拉法辛治疗癫痫性抑郁障碍疗效肯定,不良反应小,临床上可作为首选药物。

Objective To explore the efficacy, Safety and the main side effects between venlafaxine and sertraline in the treatment of epileptic depression. Methods Sixty four patients who met the criteria of CCMD- 3 for epileptic depression were randomly divided into venlafaxine group and sertraline group. They were treated respectively with venlafaxine and sertraline. At the same time, they both were received routine antiepileptic drug for six weeks. Hamilton Depression Rating Scale （HAME）. Hamilton Anxiety Rating Scale （HAMA） and Treatment Emergent Symptom Scale （TESS） were used to evaluate curative effect and adverse reactions. Results The significant effective rates of venlafaxine group and sertraline group was 83.3% and 76.7% respectively, which no significantly difference between two groups. Two cases in sertraline group have an increased frequency of epilepsy seizure while venlafaxine have no effect on the frequency of epilepsy seizure. Conclusions Venlafaxine is a safe and effective antidepressant and could be used as a first-line antidepressant in the treatment of epileptic depression.